ClinicalTrials.gg
CompletedNCT05701774Updated Oct 13, 2026

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

A Phase 3 interventional study of DCCR in Prader-Willi Syndrome, sponsored by Soleno Therapeutics, Inc.. Completed at 22 sites in 2 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Soleno Therapeutics, Inc. (part of Neurocrine Biosciences) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
15th of 58
77 · median 23
Started
2023
with 6 others
Phase 3
14 of 69
2 open now
Registered
52nd of 69
by date
Lead sponsor
5 of 69
Soleno Therapeutics, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 15th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2023, is one of 14 in phase 3, and was the 52nd registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide voluntary, written (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)
  2. Participant must:

    1. Have participated in and completed the Study C602 Randomized Withdrawal (RW) Period;
    2. Have participated in but discontinued from the Study C602 RW Period and at least 16 weeks have elapsed since the date of their randomization into the C602 RW Period; or
    3. Have participated in Study C602 OLE period, did not consent to participate in the RW Period, and at least 16 weeks have elapsed since the date of their C602 Open-Label Extension End of Treatment Visit.

Exclusion criteria

Exclusion Criteria:

  1. Positive urine pregnancy test (in females of )
  2. Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation.
  3. Participation in a clinical study of an drug (including approved drugs for unapproved uses), investigational device, or therapeutic intervention subsequent to the C602 Open-Label Extension End of Treatment Visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    DCCR

    75 - 525 mg DCCR

    Drug: DCCR

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of DCCR (adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. ( Adverse events)

    Assess the safety of DCCR by evaluating the incidence and severity of adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. Adverse events will be described by type and level of severity.

    Time frame: Baseline to End of Study or until resolution of certain adverse events

07

Study locations

22 sites
  • Soleno Clinical Site
    Orange, California 92868, United States
  • Soleno Clinical Site
    Palo Alto, California 94304, United States
  • Soleno Clinical Site
    San Diego, California 92123, United States
  • Soleno Clinical Site
    Gainesville, Florida 32608, United States
  • Soleno Clinical Site
    Atlanta, Georgia 30329, United States
  • Soleno Clinical Site
    Indianapolis, Indiana 46202, United States
  • Soleno Clinical Site
    Bethesda, Maryland 20892, United States
  • Soleno Clinical Site
    Boston, Massachusetts 02115, United States
  • Soleno Clinical Site
    Lansing, Michigan 48912, United States
  • Soleno Clinical Site
    Saint Paul, Minnesota 55102, United States
  • Soleno Clinical Site
    Paterson, New Jersey 07503, United States
  • Soleno Clinical Site
    Mineola, New York 11501, United States
  • Soleno Clinical Site
    Columbus, Ohio 43205, United States
  • Soleno Clinical Site
    Nashville, Tennessee 37212, United States
  • Soleno Clinical Site
    Dallas, Texas 75231, United States
  • Soleno Clinical Site
    Salt Lake City, Utah 84112, United States
  • Soleno Clinical Site
    Seattle, Washington 98105, United States
  • Fulbourn Hospital
    Cambridge, CB21 5EF, United Kingdom
  • Soleno Clinical Site
    Glasgow, G51 4TF, United Kingdom
  • Soleno Clinical Site
    Hull, HU3 2JZ, United Kingdom
  • Soleno Clinical Site
    London, E1 1BB, United Kingdom
  • Soleno Clinical Site
    London, SW10 9NH, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2023 to primary completion in Jan 2026, 35 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2028 → Jan 2026 and completion Jun 2028 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Jan 27, 2023
StartActual
Jan 31, 2023
Primary completionActual
Jan 12, 2026was Jun 2028
CompletionActual
Apr 29, 2026was Jun 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Sites
21 sites added, 21 sites removed
Show 21 added (17 United States, 4 United Kingdom)
  • Soleno Clinical Site · Orange, United States
  • Soleno Clinical Site · Palo Alto, United States
  • Soleno Clinical Site · San Diego, United States
  • Soleno Clinical Site · Gainesville, United States
  • Soleno Clinical Site · Atlanta, United States
  • Soleno Clinical Site · Indianapolis, United States
  • Soleno Clinical Site · Bethesda, United States
  • Soleno Clinical Site · Boston, United States
  • Soleno Clinical Site · Lansing, United States
  • Soleno Clinical Site · Saint Paul, United States
  • Soleno Clinical Site · Paterson, United States
  • Soleno Clinical Site · Mineola, United States
  • Soleno Clinical Site · Columbus, United States
  • Soleno Clinical Site · Nashville, United States
  • Soleno Clinical Site · Dallas, United States
  • Soleno Clinical Site · Salt Lake City, United States
  • Soleno Clinical Site · Seattle, United States
  • Soleno Clinical Site · Glasgow, United Kingdom
  • Soleno Clinical Site · Hull, United Kingdom
  • Soleno Clinical Site · London, United Kingdom
  • Soleno Clinical Site · London, United Kingdom
Show 21 removed
  • UC Irvine · Orange, United States
  • Stanford University · Palo Alto, United States
  • Rady Children's Hospital of San Diego · San Diego, United States
  • U of Florida Gainesville · Gainesville, United States
  • Emory Children's Center · Atlanta, United States
  • Indiana University School of Medicine · Indianapolis, United States
  • National Institutes of Health · Bethesda, United States
  • Boston Children's Hospital · Boston, United States
  • Sparrow Clinical Research Institute · Lansing, United States
  • Children's Hospital and Clinic Minnesota · St Paul, United States
  • St. Joseph's University Medical Center · Paterson, United States
  • NYU Winthrop Hospital · Mineola, United States
  • The Research Institute at Nationwide Children's Hospital · Columbus, United States
  • Vanderbilt University · Nashville, United States
  • Research Institute of Dallas · Dallas, United States
  • University of Utah · Salt Lake City, United States
  • Seattle Children's · Seattle, United States
  • The Queen Elizabeth University · Glasgow, United Kingdom
  • Hull and East Yorkshire Hospitals NHS Trust · Hull, United Kingdom
  • Royal London Hospital · London, United Kingdom
  • Chelsea and Westminster Hospital · London, United Kingdom
Oct 13, 2026
Primary completion
Jun 2028→Jan 12, 2026 (actual)
Oct 13, 2026
Study completion
Jun 2028→Apr 29, 2026 (actual)
Oct 13, 2026
Enrollment
83 (estimated)→77 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    21 sites added, 21 sites removed
    Show 21 added (17 United States, 4 United Kingdom)
    • Soleno Clinical Site · Orange, United States
    • Soleno Clinical Site · Palo Alto, United States
    • Soleno Clinical Site · San Diego, United States
    • Soleno Clinical Site · Gainesville, United States
    • Soleno Clinical Site · Atlanta, United States
    • Soleno Clinical Site · Indianapolis, United States
    • Soleno Clinical Site · Bethesda, United States
    • Soleno Clinical Site · Boston, United States
    • Soleno Clinical Site · Lansing, United States
    • Soleno Clinical Site · Saint Paul, United States
    • Soleno Clinical Site · Paterson, United States
    • Soleno Clinical Site · Mineola, United States
    • Soleno Clinical Site · Columbus, United States
    • Soleno Clinical Site · Nashville, United States
    • Soleno Clinical Site · Dallas, United States
    • Soleno Clinical Site · Salt Lake City, United States
    • Soleno Clinical Site · Seattle, United States
    • Soleno Clinical Site · Glasgow, United Kingdom
    • Soleno Clinical Site · Hull, United Kingdom
    • Soleno Clinical Site · London, United Kingdom
    • Soleno Clinical Site · London, United Kingdom
    Show 21 removed
    • UC Irvine · Orange, United States
    • Stanford University · Palo Alto, United States
    • Rady Children's Hospital of San Diego · San Diego, United States
    • U of Florida Gainesville · Gainesville, United States
    • Emory Children's Center · Atlanta, United States
    • Indiana University School of Medicine · Indianapolis, United States
    • National Institutes of Health · Bethesda, United States
    • Boston Children's Hospital · Boston, United States
    • Sparrow Clinical Research Institute · Lansing, United States
    • Children's Hospital and Clinic Minnesota · St Paul, United States
    • St. Joseph's University Medical Center · Paterson, United States
    • NYU Winthrop Hospital · Mineola, United States
    • The Research Institute at Nationwide Children's Hospital · Columbus, United States
    • Vanderbilt University · Nashville, United States
    • Research Institute of Dallas · Dallas, United States
    • University of Utah · Salt Lake City, United States
    • Seattle Children's · Seattle, United States
    • The Queen Elizabeth University · Glasgow, United Kingdom
    • Hull and East Yorkshire Hospitals NHS Trust · Hull, United Kingdom
    • Royal London Hospital · London, United Kingdom
    • Chelsea and Westminster Hospital · London, United Kingdom
    Primary completion Jun 2028→Jan 12, 2026 (now actual)
    Study completion Jun 2028→Apr 29, 2026 (now actual)
    Enrollment 83 (estimated)→77 (actual)
    + 5 other changes: identifiers, verification date, oversight details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05701774
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Jan 31, 2023
Primary completion
Jan 12, 2026
Completion
Apr 29, 2026
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazoxide choline

Start the discussion